-
Mashup Score: 1
The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a less frequent regimen that may enhance therapy adherence; ICER recommends an annual health-benefit price benchmark range of $3,600-$6,000. Bempedoic acid provides a new oral treatment option that may be helpful particularly for patients who are not able to take […]
Source: ICERCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Alzheimer's Disease - ICER - 1 year(s) ago
ICER’s analysis on the comparative clinical effectiveness and value of treatments for beta-amyloid drugs for Alzheimer’s disease. Learn more.
Source: ICERCategories: Hem/Oncs, Latest HeadlinesTweet-
@barttels2 @KasperKepp @adamfeuerstein @ProfRobHoward @LonSchneiderMD @nvillain_alz @MadhavThambiset @seb_walsh @AlbertoEspay @PhilAlz @ayton_scott @AE_MD @reshmagar @gregggonsalves @MemoryDoc @jasonkarlawish @KarlHerrup @GiovanniFrisoni @macesari @geoperry @samgandy @Gill_Livingston @Kariem_Ezzat @andrea_sturchio @AndaloussiLab @rkhamsi @r_merrick @DrLiHueiTsai @Jasonmmast @damiangarde @lauriemcginley2 @grace_huckins @aylinsdincer @PamBelluck @schrag_matthew @kathy_y_liu @dmrind @biogen @EisaiUS @naomikresge @DrMariaALZ @alzassociation @US_FDA @CMSGov @rdotinga @Medscape @drjohnm @Newsweek @95gunn Here's @icer_review 's draft evidence report on Lecanemab https://t.co/w1kiW5olB9
-
-
Mashup Score: 2ICER Publishes Final Evidence Report on Gene Therapies for Hemophilia A and B - ICER - 1 year(s) ago
ICER released a Final Evidence Report for etranacogene dezaparvovec (CSL Behring, Hemgenix) for hemophilia B. Learn more.
Source: ICERCategories: Hematologists1, Latest HeadlinesTweet-
RT @icer_review: ICER Publishes Final Evidence Report on Gene Therapies for Hemophilia A and B: https://t.co/uRFN8AJQTY
-
-
Mashup Score: 3ICER to Assess Treatments for Alzheimer's Disease - ICER - 2 year(s) ago
Report will be subject of CTAF meeting in July 2022; Draft Scoping Document open to public comment until January 19, 2022.
Source: ICERCategories: Hem/Oncs, Latest HeadlinesTweet-
@barttels2 @geoperry @InnoTalker @MadhavThambiset @samgandy @ProfRobHoward @MariaGlymour @trishgreenhalgh @JohnCendpts @Neuronologist1 @JamieSmythF @EnnalsEthan @AlbertoEspay @MemoryDoc @LonSchneiderMD @jasonkarlawish @PamBelluck @RebeccaDRobbins @Gill_Livingston @PhilAlz @macesari @drgdanielgeorge @MedinaRiojaMD @joewalkerWSJ @alleolabs @LifeSciVC @DrewQJoseph Meanwhile, in other news, @icer_review 's report on Lecanemab is expected to be published on Dec 22 https://t.co/rNTLTOm1jC
-
-
Mashup Score: 6Obesity Management - ICER - 2 year(s) ago
ICER’s analysis on the comparative clinical effectiveness and value of treatments for obesity management. Learn more.
Source: ICERCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @MichaelAlbertMD: Finally reviewed the recent ICER report on FDA-approved drugs for LT obesity treatment: https://t.co/mLuwsTz5xX Some…
-
-
Mashup Score: 1Obesity Management - ICER - 2 year(s) ago
ICER’s analysis on the comparative clinical effectiveness and value of treatments for obesity management. Learn more.
Source: ICERCategories: Cardiologists, Latest HeadlinesTweet-
RT @MichaelAlbertMD: Finally reviewed the recent ICER report on FDA-approved drugs for LT obesity treatment: https://t.co/mLuwsTz5xX Some…
-
-
Mashup Score: 2ICER Publishes Evidence Report on Treatments for Amyotrophic Lateral Sclerosis - ICER - 2 year(s) ago
Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds for cost-effectiveness if priced between $9,100 – $30,600 per year.
Source: ICERCategories: Latest Headlines, Rare DiseaseTweet-
.@icer_review meeting on pricing issues for Radicava ORS and potentially AMX0035. All day Friday Aug 19. Be there or be square. https://t.co/bIyvy5gSGu
-
-
Mashup Score: 3ICER Publishes Evidence Report on Treatments for Amyotrophic Lateral Sclerosis - ICER - 2 year(s) ago
Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds for cost-effectiveness if priced between $9,100 – $30,600 per year.
Source: ICERCategories: Latest Headlines, Rare DiseaseTweet-
RT @icer_review: ICER Publishes Evidence Report on Treatments for Amyotrophic Lateral Sclerosis: https://t.co/dK0xQVNIZY
-
-
Mashup Score: 3
— Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, net of rebates and discounts, for alirocumab in patients with a recent acute coronary event: $2,300-$3,400 per year if used to treat all patients who meet trial eligibility criteria, and $4,500-$8,000 per year if used to treat […]
Source: ICERCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: -Based Price Benchmark for Alirocumab #PCSK9i - #ICER https://t.co/lXMSSYosnZ
-
-
Mashup Score: 0ICER Publishes Protocol for Annual Assessment of Drug Coverage Policies That Present Barriers to Fair Access - ICER - 2 year(s) ago
ICER will evaluate whether the 15 largest US commercial payers, the 2 largest state health exchange plans, and the Department of Veterans Affairs have formularies and procedures that provide appropriate access to the prescription drugs reviewed by ICER in 2020.
Source: ICERCategories: Cardiologists, Latest HeadlinesTweet-
#FairDrugCoverage Policies That Present Barriers to Fair Access #ICER https://t.co/NF5ThncPwR
-
Absolutely spot on! @icer_review health economic analysis clearly states Bempedoic Acid is not cost-effective https://t.co/4pV4XGcRB0 https://t.co/EOgGKFG9Ii